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Abstract
Cholera toxin (CT) travels as an intact AB5 protein toxin from the cell surface to the endoplasmic reticulum (ER) of an
intoxicated cell. In the ER, the catalytic A1 subunit dissociates from the rest of the toxin. Translocation of CTA1 from the ER
to the cytosol is then facilitated by the quality control mechanism of ER-associated degradation (ERAD). Thermal instability
in the isolated CTA1 subunit generates an unfolded toxin conformation that acts as the trigger for ERAD-mediated
translocation to the cytosol. In this work, we show by circular dichroism and fluorescence spectroscopy that exposure to 4-
phenylbutyric acid (PBA) inhibited the thermal unfolding of CTA1. This, in turn, blocked the ER-to-cytosol export of CTA1
and productive intoxication of either cultured cells or rat ileal loops. In cell culture studies PBA did not affect CT trafficking
to the ER, CTA1 dissociation from the holotoxin, or functioning of the ERAD system. PBA is currently used as a therapeutic
agent to treat urea cycle disorders. Our data suggest PBA could also be used in a new application to prevent or possibly
treat cholera.
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Introduction
AB toxins consist of an enzymatic A subunit and a cell-binding
B subunit [1]. These toxins are secreted into the extracellular
milieu, but they act upon targets within the eukaryotic cytosol.
The toxins must therefore cross a membrane barrier in order to
function. Some AB toxins travel by vesicle carriers from the cell
surface to the endoplasmic reticulum (ER) before passing into the
cytosol [2]. These ER-translocating toxins enter the ER as intact
holotoxins, but environmental conditions in the ER promote the
dissociation of the catalytic subunit from the rest of the toxin.
Translocation of the isolated A chain from the ER to the cytosol is
then facilitated by the quality control mechanism of ER-associated
degradation (ERAD) [3]. Exported ERAD substrates are normally
targeted for ubiqutin-dependent proteasomal degradation, but the
A chains of ER-translocating toxins have few lysine residues for
ubiquitin conjugation and thus effectively avoid degradation by
the 26S proteasome [4–7].
Cholera toxin (CT) is an AB5-type, ER-translocating toxin
[8,9]. Its A subunit is proteolytically nicked to generate a
disulfide-linked A1/A2 heterodimer. The enzymatic A1 subunit
dissociates from the rest of the toxin in the ER and enters the
cytosol where it ADP-ribosylates the stimulatory a subunit of the
heterotrimeric G protein (Gsa). Adenylate cyclase is activated
by the ADP-ribosylated form of Gsa, which in turn leads to
elevated levels of intracellular cAMP. A chloride channel, the
cystic fibrosis transmembrane regulator, opens in response to
the signaling events triggered by high cAMP levels. The osmotic
movement of water which follows chloride efflux into the
intestinal lumen generates the profuse watery diarrhea of
cholera.
Thermal instability in the isolated CTA1 subunit serves as the
trigger for ERAD-mediated translocation to the cytosol [10,11].
CTA1 is held in a stable conformation by its association with
CTA2/CTB5, but it unfolds spontaneously at physiological
temperature when it is released from the rest of the toxin in the
ER [11–13]. The loss of CTA1 tertiary structure that accompanies
its dissociation from the holotoxin identifies CTA1 as a misfolded
protein for ERAD processing [10]. After ERAD-mediated
translocation to the cytosol, CTA1 interacts with ADP-ribosylation
factors and possibly other host factors in order to regain a folded,
active conformation [11,14,15].
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e18825Because of its central role in ERAD-mediated toxin transloca-
tion, CTA1 thermal instability represents a promising target for
anti-toxin therapeutics. Inhibition of CTA1 unfolding in the ER
would prevent its recognition by the ERAD system, its
translocation to the cytosol, and, thus, its cytopathic effect. We
recently used glycerol, a chemical chaperone that stabilizes protein
structures and disrupts ERAD-substrate interactions, to provide
proof-of-principle for this therapeutic strategy: glycerol treatment
specifically stabilized the tertiary structure of CTA1, which in turn
prevented CTA1 translocation to the cytosol and productive
intoxication [10]. Acidic pH likewise prevented the thermal
disordering of CTA1 tertiary structure and CTA1 translocation to
the cytosol [16]. These results strongly suggest that cholera could
be prevented or treated with therapeutic agents that stabilize the
tertiary structure of CTA1.
The overall aim of this work was to determine if a therapeutic
chemical chaperone could be used to block the cytopathic effects
of CT. Here, we report that 4-phenylbutyric acid (PBA) inhibits
the thermal unfolding of CTA1, the ER-to-cytosol translocation of
CTA1, and CT intoxication. PBA is a chemical chaperone and a
therapeutic agent approved by the Food and Drug Administration
(FDA) for the management of urea cycle disorders [17,18]. The
therapeutic value of PBA in treating these disorders relates to its
function as an ammonia scavenger rather than its ability to
function as a chemical chaperone. In vitro, PBA bound to the CT
holotoxin and the CTA1 polypeptide with nM affinity but did not
bind to the CTB pentamer. In vivo, PBA effectively blocked fluid
accumulation in the physiological ileal loop model of CT
intoxication. PBA could thus represent a novel therapeutic agent
for the prevention or treatment of cholera.
Results
PBA binds directly to CT and CTA1
To determine if PBA binds directly to CTA1, we used the
method of surface plasmon resonance (SPR). CT, CTA1, and the
CTB pentamer were each appended to separate SPR sensor slides.
Ligand binding to a toxin-coated sensor slide increases the mass on
the slide, and this in turn generates a change in the resonance
angle of the reflected light which is recorded as the refractive index
[19]. An increase in the refractive index unit (RIU) was detected
when PBA was perfused over the CT and CTA1 sensor slides
(Figs. 1A–B). However, no change in the RIU was recorded when
100 mM PBA was perfused over the CTB5 sensor slide (Fig. 1C). A
strong positive signal was obtained when an anti-CTB antibody
was perfused over the CTB5 sensor slide, thus confirming the
presence of CTB5 on our plate. These results demonstrated that
PBA binds directly to CTA1 and strongly suggested that PBA
binding to the CT holotoxin is mediated by the A1 subunit rather
than the B pentamer.
The SPR experiments of Figures 1A–B were used to determine
the binding affinity of PBA for CT and CTA1. As shown in
Table 1, an equilibrium dissociation constant of about 10 nM was
calculated for the interaction between PBA and either CT or
CTA1. Further analysis of the SPR data indicated that 18
molecules of PBA bind to each molecule of CTA1. The high
affinity interaction between PBA and CT/CTA1 suggested that
PBA could serve as an anti-toxin therapeutic agent.
PBA inhibits the thermal unfolding of CTA1
Circular dichroism (CD) and fluorescence spectroscopy were
used to examine the effect of PBA on CTA1 thermal stability.
Measurements were taken on a reduced CTA1/CTA2 heterodi-
mer during a step-wise increase in temperature from 18uCt o
60uC. The 22 kDa CTA1 subunit is much larger than the 5 kDa
CTA2 subunit, so it makes a major contribution to the CD
spectra. Furthermore, CTA1 contains all three of the tryptophan
residues that contributed to the fluorescence emission spectra.
Reduction of the CTA1/CTA2 disulfide bond occurred when a
final concentration of 10 mM b-mercaptoethanol (b-ME) was
added to the toxin sample. This step was performed in order to
mimic the holotoxin disassembly event that occurs in the ER [20–
22]. Previous work has shown that complete reductive separation
of CTA1 from CTA2 occurs within 1 minute of b-ME addition
[11]. Control experiments further confirmed that PBA did not
prevent the reductive separation of CTA1 from CTA2 (Fig. S1).
The covalent association of CTA1 with CTA2 provides a degree
of conformational stability to CTA1 [11,12], so a shift in the CD
spectra of the disulfide-linked CTA1/CTA2 heterodimer was
apparent after b-ME addition at 18uC (Fig. 2A, C). This spectral
shift did not occur for the PBA-treated toxin (Fig. 2D, F), which
provided preliminary evidence for the stabilizing influence of PBA
on the structure of CTA1.
By near-UV CD, we recorded a tertiary structure transition
temperature (Tm; the midpoint of transition between folded and
unfolded conformations) of 30uC for reduced CTA1/CTA2
(Fig. 2A, G) and a Tm of 36uC for reduced and PBA-treated
CTA1/CTA2 (Fig. 2D, G). Fluorescence spectroscopy document-
ed a red shift to the maximum emission wavelength (lmax)o f
Figure 1. PBA binds to CT and CTA1 but not to CTB5. PBA was perfused over SPR sensor slides that had been coated with CT (A), CTA1 (B), or
CTB5 (C). PBA concentrations of 0.1, 1, 10, 100, and 1000 mM were used in panels A and B; 100 mM PBA was used for panel C. As a positive control, an
anti-CTB antibody was also perfused over the sensor slide in panel C. PBA was removed from the perfusion buffer either 390 sec (A and B) or 130 sec
(C) into the experiment. In panels A and B, measurements collected from three independent experiments are shown. The orange lines represent best
fit curves for the presented data.
doi:10.1371/journal.pone.0018825.g001
Use of PBA as a Toxin Inhibitor
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and a Tm of 41uC for PBA-treated CTA1 (Fig. 2E, H). As assessed
by far-UV CD, the toxin secondary structure exhibited a Tm of
35uC for reduced CTA1/CTA2 (Fig. 2C, I) and a Tm of 44uC for
reduced and PBA-treated CTA1/CTA2 (Fig. 2F, I). These results
demonstrated that PBA inhibits the thermal perturbation of both
CTA1 secondary and tertiary structures.
CD and fluorescence spectroscopy measurements were also
conducted with reduced CTA1/CTA2 heterodimers incubated in
the presence of 1 or 10 mM PBA. The Tm values derived from all
of our biophysical experiments are presented in Table 2, which
Table 1. Binding affinities between PBA and CT or CTA1.
Binding Parameter ka (1/Ms) kd (1/s) KD (nM)
PBA+CT 1.21610
5 1.38610
23 11
PBA+CTA1 1.55610
5 1.31610
23 9
doi:10.1371/journal.pone.0018825.t001
Figure 2. PBA inhibits the thermal unfolding of reduced CTA1/CTA2. The temperature-induced unfolding of a reduced CTA1/CTA2
heterodimer in the absence (A–C) or presence (D–F) of 100 mM PBA was monitored by near-UV CD (A, D), fluorescence spectroscopy (B, E), and far-UV
CD (C, F). A final concentration of 10 mM b-ME was added to the buffer after an initial 18uC measurement was taken with the disulfide-linked CTA1/
CTA2 heterodimer, as marked with asterisks. The change in color from blue to red corresponds to a change in temperature from 18uCt o6 0 uC.
Thermal unfolding profiles for the reduced CTA1/CTA2 heterodimer in the absence (red) or presence (green) of 100 mM PBA were derived from the
data presented in panels A–F. (G): For near-UV CD analysis, the mean residue molar ellipticities at 280 nm ([h]280) were plotted as a function of
temperature. (H): For fluorescence spectroscopy, the maximum emission wavelength (lmax) was plotted as a function of temperature. (I): For far-UV
CD analysis, the mean residue molar ellipticities at 220 nm ([h]220) were plotted as a function of temperature.
doi:10.1371/journal.pone.0018825.g002
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although PBA conferred some thermal stability to the secondary
and tertiary structures of CTA1 at 1 and 10 mM concentrations,
the maximal stabilization of CTA1 was obtained with 100 mM
PBA. Thus, at all tested concentrations, PBA provided some
degree of conformational stability to the reduced CTA1 subunit.
Previous work has suggested that the thermal unfolding of
CTA1 begins with a localized loss of structure in the C-terminal
A13 subdomain [16]. To determine if this region was involved with
the stabilizing effect of PBA on CTA1 structure, we repeated our
biophysical experiments with a His-tagged CTA1 construct
lacking the A13 subdomain [23]. In contrast to the results
obtained with a reduced CTA1/CTA2 heterodimer (Fig. 2) or
with a full-length His-tagged CTA1 construct (Fig. S2), PBA did
not alter the thermal unfolding profiles for the secondary and
tertiary structures of the truncated CTA1 construct (Fig. S3).
Thus, PBA appeared to stabilize CTA1 by preventing the initial
temperature-induced loss of structure in the C-terminal A13
subdomain.
Additional CD and fluorescence spectroscopy measurements
were performed in order to determine whether PBA could induce
unfolded CTA1 to regain its initial conformation. For these
experiments, the reduced CTA1/CTA2 heterodimer was heated
to 37uC. Near-UV CD, fluorescence spectroscopy, and far-UV
CD were then used to assess the conformational state of reduced
CTA1/CTA2 before and after the addition of 100 mM PBA. As
shown in Figure 3, PBA did not promote the refolding of a
thermally disordered CTA1 subunit. No significant changes to the
structure of CTA1 occurred five minutes (not shown) or one hour
after the addition of PBA at 37uC. Cooling CTA1 from 37uCt o
18uC will allow the toxin to regain a folded conformation (Fig. S4),
so the unfolding of CTA1 at 37uC is a reversible process. Thus,
PBA will stabilize the folded CTA1 subunit but will not facilitate
the renaturation of an unfolded CTA1 subunit.
PBA inhibits CTA1 translocation to the cytosol
Our collective data suggested that PBA can bind to holotoxin-
associated CTA1 and can then prevent the spontaneous thermal
unfolding of the dissociated CTA1 subunit. By our model, CTA1
stabilization would prevent its recognition by the ERAD system
and its ERAD-mediated translocation to the cytosol. To test this
prediction, we performed a translocation assay to monitor the ER-
to-cytosol export of CTA1 in the absence or presence of PBA
(Fig. 4). Surface-bound CT was chased into HeLa cells for two
hours before organelle and cytosolic fractions were generated from
the intoxicated cells. Western blot controls demonstrated that
protein disulfide isomerase (PDI), a soluble ER resident protein,
was found only in the pellet fraction which contained intact
membrane-bound organelles (Fig. 4A). As expected, the cytosolic
protein Hsp90 was found in the supernatant fraction which
contained the cytosol (Fig. 4A). Our protocol could thus effectively
segregate the cell extracts into distinct organelle and cytosolic
fractions.
Only a minor pool of surface-bound CT (,5%) is transported to
the ER; the majority of internalized toxin is instead degraded in
the lysosomes [24,25]. We accordingly used the highly sensitive
method of SPR to detect CTA1 in the cytosolic fractions from
untreated and PBA-treated cells (Fig. 4B). For this experiment,
SPR sensor slides were coated with an anti-CTA antibody. The
cytosolic fractions from our cell extracts were then perfused over a
sensor slide in order to detect the translocated, cytosolic pool of
CTA1. No signal was obtained from the cytosol of unintoxicated
cells or from the cytosol of cells intoxicated in the presence of
brefeldin A (BfA), a drug that blocks toxin transport to the ER
translocation site [24,25]. In contrast, CTA1 was consistently
detected in the cytosol of untreated HeLa cells after 2 hours of
toxin internalization (n=3). The cytosol from PBA-treated cells
produced a weak SPR signal that was substantially attenuated in
comparison to the signal obtained from the untreated control cells.
Table 2. Dose-dependent thermal stabilization of CTA1 by
PBA.
Transition Temperature (6C)
mM PBA Near-UV CD Fluorescence Spectroscopy Far-UV CD
0 30.0 36.0 35.0
1 33.0 37.5 37.0
10 35.0 38.5 39.0
100 36.0 41.0 44.0
doi:10.1371/journal.pone.0018825.t002
Figure 3. PBA does not promote the refolding of a thermally disordered CTA1 subunit. Near-UV CD (A), fluorescence spectroscopy (B),
and far-UV CD (C) measurements of the CTA1/CTA2 heterodimer were taken at 18uC (blue spectra), 18uC after the addition of 10 mM b-ME (green
spectra), after heating reduced CTA1/CTA2 to 37uC (yellow spectra), and one hour after the addition of 100 mM PBA to reduced CTA1/CTA2 at 37uC
(red spectra). The substantial decrease in fluorescence intensity that occurred after an hour at 37uC in the presence of PBA likely resulted from the
inherent temperature dependence of tryptophan fluorescence [50]. Notably, the lmax red shift which accompanied the heating of reduced CTA1/
CTA2 to 37uC was not reversed by the subsequent addition of PBA at 37uC.
doi:10.1371/journal.pone.0018825.g003
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and PBA partially inhibited, the delivery of CTA1 to the cytosol.
The association rate constant (ka) derived from SPR data is
proportional to ligand concentration [19], so we calculated the
levels of cytosolic CTA1 from a standard curve of the ka values for
the CTA standards (Fig. S5). With this method, we estimated that
3-fold less CTA1 was in the cytosol of PBA-treated cells than in the
cytosol of untreated control cells. Thus, PBA effectively prevented
CTA1 from reaching the cytosol of intoxicated cells.
PBA does not inhibit retrograde toxin trafficking to the
ER, PDI function, or ERAD activity
Control experiments were performed to ensure that PBA did
not affect host-toxin interactions occurring before the translocation
event. CT-treated HeLa cells were processed as described for the
aforementioned SPR-based translocation assay, except in this case
the pellet/organelle fractions were resolved by non-reducing SDS-
PAGE and probed by Western blot with an anti-CTA antibody.
As shown in Figure 5, reduced CTA1 was recovered from PBA-
treated cells but not from BfA-treated cells. Reduction of the
CTA1/CTA2 disulfide bond occurs in the ER [20,21], so the
presence of reduced CTA1 is indicative of CT transport to the ER.
This experiment therefore demonstrated that, as expected, BfA
prevented toxin trafficking to the ER. In contrast, PBA did not
block CT transport from the cell surface to the ER. In fact, we
consistently detected slightly more reduced CTA1 in PBA-treated
cells than in the untreated control cells (n=4). This indicated that
CTA1 accumulated in the ER of PBA-treated cells, which was
consistent with the PBA-induced block of CTA1 translocation
(Fig. 4) and CTA1 secretion (Fig. S6).
Reduction of the CTA1/CTA2 disulfide bond is not sufficient
for holotoxin disassembly; reduced CTA1 must be removed from
CTA2/CTB5 by PDI [22]. To determine whether the PBA-
induced block of CTA1 translocation was due to an inhibition of
holotoxin disassembly, we used SPR to detect the PDI-mediated
dissociation of CTA1 from CTA2/CTB5 (Fig. 6). When reduced
PDI was perfused over a CT-coated SPR sensor slide, an increase
in the RIU was followed by a precipitous drop in signal below the
baseline value which represented the mass of the CT holotoxin.
This indicated that the initial binding of PDI to the CT holotoxin
quickly resulted in the loss of both PDI and a component of the
Figure 4. PBA blocks CTA1 translocation to the cytosol. HeLa cells were pulse-labeled at 4uC for 30 min with 1 mg/ml of CT. The cells were
then chased for 2 hr at 37uC in toxin-free medium that contained no additions, 100 mM PBA, or 5 mg/ml of BfA. Selective permeabilization of the
plasma membrane with digitonin was used to partition cell extracts into separate membrane (pellet; P) and cytosolic (supernatant; S) fractions. (A):
Both fractions were probed by Western blot to establish the distributions of cytosolic marker Hsp90 and ER marker PDI. (B): An SPR sensor slide
coated with an anti-CTA antibody was used to detect the cytosolic pool of CTA1 from untreated (no treatment) or drug-treated cells. CTA standards
(100, 10, 1, and 0.1 ng/ml) were perfused over the sensor slide as positive controls; only the 1 and 0.1 ng/ml standards are shown for scaling
purposes. A cytosolic fraction from unintoxicated cells was also generated for this experiment. One of three representative experiments is shown. At
the end of each experiment, bound sample was stripped from the sensor slide.
doi:10.1371/journal.pone.0018825.g004
Figure 5. PBA does not block reduction of the CTA1/CTA2
disulfide bond in the ER. HeLa cells pulse-labeled at 4uC with
recombinant CT were chased for 2 hr at 37uC in medium containing no
additions (no treatment), 100 mM PBA, or 5 mg/ml of BfA. Membrane
fractions from digitonin-permeabilized cells were resolved by non-
reducing SDS-PAGE and probed by Western blot with an anti-CTA
antibody. A purified, disulfide-linked CTA1/CTA2 heterodimer was also
run as a control. We consistently detected slightly more reduced CTA1
in PBA-treated cells than in the untreated control cells (n=4).
doi:10.1371/journal.pone.0018825.g005
Use of PBA as a Toxin Inhibitor
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additions of anti-PDI and anti-CTA antibodies to the sensor slide
confirmed this interpretation, as neither antibody bound to the
PDI-treated toxin. In contrast, the B pentamer remained on the
slide as demonstrated by detection with an anti-CTB antibody.
Since this experiment was performed with 100 mM PBA present in
the perfusion buffer, we concluded that PBA binding to the CT
holotoxin does not prevent the chaperone-assisted dissociation of
CTA1 from CTA2/CTB5.
To ensure that PBA did not induce a general block of ERAD
activity, we performed another translocation assay with plasmid-
expressed CTA1. This CTA1 construct contains an N-terminal
signal sequence for co-translational insertion into the ER lumen
[23]. Previous work has demonstrated that the entire detectable
pool of expressed CTA1 is initially delivered to the ER where the
signal sequence is removed [26]. The ER-localized toxin is then
translocated back into the cytosol. We predicted that the ER-to-
cytosol export of plasmid-expressed CTA1 would not be affected
by PBA treatment because (i) co-translational insertion into the ER
involves unfolded protein conformations; (ii) the incubation
temperature of 37uC would prevent CTA1 from attaining a
folded state after insertion into the ER; and (iii) PBA does not
induce unfolded CTA1 to assume its native conformation (Fig. 3).
Plasmid-expressed CTA1 would thus enter the ER in an unfolded
state and would retain that conformation even in the presence of
PBA, thereby promoting its ERAD-mediated translocation to the
cytosol. As shown in Fig. 7, nearly equivalent amounts of plasmid-
expressed CTA1 were exported to the cytosol of either untreated
or PBA-treated cells. This result indicated that PBA does not block
overall ERAD activity, but specifically inhibits the toxin-ERAD
interaction that occurs with exogenously applied CT holotoxin.
This specific inhibition most likely involves PBA-mediated
stabilization of the folded CTA1 conformation which initially
enters the ER as part of the CT holotoxin.
The control experiments presented in Figures 5, 6, 7 collectively
demonstrated that PBA does not substantially inhibit toxin
trafficking to the ER, toxin disassembly in the ER, or overall
ERAD activity. PBA thus appeared to specifically block toxin
entry into the cytosol at the level of ER-to-cytosol translocation.
PBA blocks CT intoxication of cultured cells and ileal
loops
The PBA-induced inhibition of toxin translocation would
prevent CTA1 from entering the cytosol where its Gsa target is
located. PBA should therefore inhibit the cytopathic effects of CT.
To determine the inhibitory effect of PBA on CT intoxication, we
monitored cAMP levels in HeLa cells challenged with varying
concentrations of CT in the absence or presence of PBA (Fig. 8A).
A half-maximal effective concentration (EC50) of 4 ng CT/ml was
calculated for cells exposed to toxin alone. In contrast, PBA-
treated cells were highly resistant to CT. At the EC50, cells
exposed to just 1 mM PBA were 10-fold more resistant to CT than
the untreated control cells. Intoxicated cells treated with 10 mM
Figure 6. PBA does not block the dissociation of CTA1 from
CTA2/CTB5. After appending CT to a GM1-coated SPR sensor slide, a
baseline measurement corresponding to the mass of the holotoxin was
recorded. Reduced PDI was then perfused over the slide in the presence
of 100 mM PBA. PDI was present in the perfusion buffer until
approximately 500 sec into the experiment, after which it was replaced
with sequential additions of an anti-PDI antibody, an anti-CTA antibody,
and an anti-CTB antibody (arrowheads). One of two representative
experiments is shown.
doi:10.1371/journal.pone.0018825.g006
Figure 7. PBA does not inhibit the translocation of an ER-
localized CTA1 construct. CHO cells were transfected with a plasmid
encoding a CTA1 subunit appended with an ER-targeting signal
sequence. Permeabilization of the plasma membrane with digitonin
was used to partition cell extracts into separate organelle (pellet; P) and
cytosolic (supernatant; S) fractions. The distribution of CTA1 immuno-
precipitated from transfected cells after a 1 hr radiolabeling was
visualized and quantified by SDS-PAGE with PhosphorImager analysis.
Experiments were performed with untreated cells and cells exposed to
100 mM PBA. The means 6 standard errors of the means of four
independent experiments are presented in the graph.
doi:10.1371/journal.pone.0018825.g007
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cells. Even at the highest toxin concentration of 100 ng/ml, cells
treated with 10 mM PBA only produced 40% of the maximal
cAMP signal obtained from the control cells. Cells treated with
10 mM PBA therefore required at least 25-fold higher concentra-
tions of toxin to reach the EC50 obtained for the untreated control
cells. Dose-dependent disruptions to CT intoxication were also
recorded for cells exposed to 100 or 1000 mM PBA. Additional
control experiments demonstrated that PBA did not inhibit the
forskolin-induced elevation of intracellular cAMP: cells treated
with 100 mM PBA and forskolin produced 97% of the cAMP levels
recorded for cells treated with forskolin alone. Forskolin activates
adenylate cyclase without the input of Gsa, so this observation
demonstrated that PBA did not directly inhibit the production of
cAMP by adenylate cyclase. Thus, PBA provided strong
protection against CT in a cell culture system.
To examine the therapeutic potential of PBA as an anti-CT
agent, we employed a physiological ileal loop model of CT
intoxication. Rats were injected intraperitoneally with a concentra-
tion of PBA that has previously been used in animal studies: 200 mg
PBA/kgbodyweight[27–29].CTwasinjected directlyinto theileal
loop 40 minutes after the intraperitoneal injection of PBA, and the
effects of intoxication were assessed seven hours after toxin
challenge. As shown in Figure 8B, the intestinal distension and
fluid accumulation induced by CT was dramatically attenuated in
PBA-treated rats. The effects of intoxication were also substantially
reduced when PBA and CT were co-injected directly into the
intestinal loops (Fig. 8C). For both methods of drug delivery, CT-
induced fluid accumulation was reduced by about 75% in
comparison to control rats that were exposed to CT but not PBA.
These results demonstrated that PBA, an FDA-approved therapeu-
tic, can provide substantial in vivo protection against CT.
Discussion
PBA is an FDA-approved drug for the treatment of urea cycle
disorders [18]. The therapeutic value of PBA in treating these
disorders relates to its function as an ammonia scavenger.
However, PBA is also a chemical chaperone that can stabilize
protein structures. In this capacity, PBA has been evaluated as a
potential therapeutic for the treatment of many genetic diseases
involving the ERAD-mediated degradation of mutant proteins
that appear misfolded yet retain at least some wild-type function
[17]. The PBA-mediated stabilization of these mutant proteins
would, in theory, disrupt ERAD-substrate interactions and
consequently result in the secretion of a functional protein. The
release of a previously missing protein would correct the
phenotype of the genetic defect and thus cure the disease. Since
accumulating evidence suggests that CTA1 is processed as a
typical ERAD substrate, we took a conceptually similar approach
with CT: the PBA-mediated stabilization of CTA1 was predicted
to disrupt ERAD-substrate interactions and thereby prevent the
ERAD-mediated disease state. This strategy views cholera as a
unique type of protein folding disease and suggests a new, anti-
toxin application for a current clinical reagent.
At a concentration of 100 mM, PBA inhibited the thermal
unfolding of CTA1, the ER-to-cytosol export of CTA1, and CT
intoxication of cultured cells. Some inhibitory effects on CTA1
unfolding and CT intoxication were also observed with 1 and
10 mM PBA. Retrograde toxin trafficking to the ER, holotoxin
disassembly by PDI, and ERAD activity in general were not
altered by 100 mM PBA. However, we found that the stabilized
pool of CTA1 was not efficiently secreted from PBA-treated cells.
In contrast, we previously reported that glycerol-treated cells
secreted more CTA1 than untreated control cells [10]. The
different effects of PBA and glycerol on CTA1 secretion likely
relates to their distinct modes of protein stabilization: PBA
physically binds to the protein whereas glycerol forms a hydration
shell around the protein [30]. The additional mass resulting from
PBA interaction could possibly interfere with the packaging of
stabilized CTA1 into carrier vesicles for secretory transport.
Alternatively, different conformations for glycerol-stabilized CTA1
vs. PBA-stabilized CTA1 could promote toxin secretion from only
glycerol-treated cells. The retention of PBA-stabilized CTA1
within the endomembrane system did not reduce cell viability over
a 48 hour period as assessed by MTT assay (n=2), possibly
because the low levels of CT that traffic to the ER are not
sufficient to overwhelm the transport and quality control functions
of the secretory pathway.
Figure 8. PBA inhibits CT intoxication. (A): HeLa cells were incubated with CT in the absence or presence of the stated PBA concentrations. After
2 hr of continual toxin exposure, toxicity was assessed from the elevated levels of intracellular cAMP. The means 6 standard errors of the means of
four independent experiments with triplicate samples are shown. (B): PBA was injected into the rat peritoneal cavity at a concentration of 0.18 M,
which corresponded to 200 mg PBA/kg body weight. After 40 min, surgically sealed sections of intestine from mock-treated or PBA-treated rats were
injected with 3 mg/ml of CT. An additional mock-treated rat was injected with PBS alone. Morphological examination (inset) and the calculation of
fluid accumulation were performed 7 hr after toxin challenge. Results presented in the graph represent the averages 6 standard deviations of data
obtained from 4 rats per condition. (C): Ileal loops were injected with 1 mg/ml of CT or co-injected with CT and either 1 or 1.3 mM PBA. The evaluation
of intoxication was performed as described in panel (B).
doi:10.1371/journal.pone.0018825.g008
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the unfolded protein response, and inhibits chloride efflux from
the cystic fibrosis transmembrane regulator. Each of these effects
could influence host-CT interactions, but the concentration and
duration of PBA treatment used in our studies is insufficient to
elicit these off-target effects. We documented the block of CTA1
translocation and CT intoxication with two hour cell culture
assays utilizing 100 mM PBA. In contrast, PBA-induced alterations
to chaperone expression require a 48 hour exposure to at least
0.5 mM PBA [31,32]. Alterations to the unfolded protein response
require a 24 hour exposure to 10 mM PBA [33] or a 72 hour
exposure to 2 mM PBA [34]. Inhibition of the cystic fibrosis
transmembrane regulator in polarized epithelial cells only occurs
after a 24 hour exposure to 5 mM PBA [35]. The low
concentration of PBA required to stabilize CTA1, combined with
the specific interaction between PBA and CTA1 (i.e., no PBA
binding to CTB5 and no general effect on ERAD), thus minimizes
off-target effects while still providing substantial cellular resistance
to CT.
Exposure to 100 mM PBA generated a 3-fold reduction in the
efficiency of CTA1 translocation to the cytosol. This, in turn,
promoted a greater than 25-fold level of cellular resistance to CT.
PBA-induced toxin resistance was also demonstrated in the
physiological ileal loop model of intoxication. Previous work has
shown that high levels of toxin resistance can be achieved without
a complete block of toxin access to the cytosol [10,36–38].
Furthermore, as recently shown for the plant toxin ricin, moderate
levels of drug-induced toxin resistance in cell culture can
correspond to high levels of drug-induced toxin resistance in an
animal model [39]. We therefore expect that PBA will provide
substantial protection against V. cholerae in an animal model of
infection.
The maximum FDA-approved dosage of PBA is 20 g/day,
which in clinical studies represented 10.6 to 13.8 g/M
2/d. The
drug was administered orally three to four times a day in the form
of 500 mg tablets. With this regimen, patients attained serum PBA
concentrations of 600–1,700 mM [40,41]. It should therefore be
possible to orally administer, at dosages well below the FDA-
approved limit, a concentration of PBA that can inhibit CTA1
unfolding and CT intoxication in intestinal epithelial cells.
One limitation of a PBA-based therapeutic strategy is the timing
of the inhibitory effect: PBA must act on the holotoxin before
dissociation and translocation of the CTA1 subunit. While this
would be acceptable for a preventative measure, its utility in
treating patients already exposed to CT could be more limited.
However, a number of observations suggest a post-exposure
inhibition of CT might at least attenuate the effects of cholera. The
rapid turnover of ADP-ribosylated Gsa [42] and the removal of
ADP-ribose modifications by ADP-ribosyl(arginine)protein hydro-
lase [43] suggest that the activated form of Gsa can be cleared
from the intoxicated cell, provided that CTA1 is also removed
from the cytosol. Experiments demonstrating a correlation
between toxin persistence in the cytosol and the extent of
intoxication further support this possibility: the diminished
potency of CT and recombinant CT constructs which are rapidly
degraded in the cytosol indicates the cytosolic pool of toxin must
be maintained at a certain level for optimal intoxication [6,37,44].
This precedent has been established for other virulence factors
such as Shiga toxin [45] and the SpvB effector protein from
Salmonella [46]. Thus, PBA application after the initial exposure
to Vibrio cholerae/CT would prevent additional toxin from reaching
the cytosol of an intoxicated cell, and this effect might attenuate
the effects of intoxication. Attenuation of the disease state could
also occur by the protective effect PBA would extend to newly
differentiated enterocytes in the intestinal epithelium of an infected
individual.
Our collective data indicates that PBA binds to the holotoxin-
associated CTA1 subunit. The PBA-bound CTA1 subunit does
not undergo thermal unfolding after toxin disassembly in the ER,
and, as such, does not active the ERAD system. Toxin
translocation to the cytosol is consequently blocked, which results
in cellular protection against CT. PBA represents a promising
therapeutic to prevent or possibly treat cholera because (i) it is
already approved for human use; (ii) it is effective against CT at
concentrations that can be attained in patients; (iii) it exhibits low
nM affinity for CT/CTA1; and (iv) it inhibits CT in the
physiological ileal loop model of intoxication. Future studies with
animal models will determine whether PBA can be used to treat, as
well as prevent, cholera.
Materials and Methods
Ethics statement
Ileal loop experiments were performed with approval from the
Institutional Animal Care and Use Committee from the Center of
Research and Advanced Studies (Centro de Investigacion y de
Estudios Avanzados del IPN), protocol number 0364-07.
Materials
The rabbit anti-CTA antibody, rabbit anti-CTB antibody, BfA,
and ganglioside GM1 were purchased from Sigma-Aldrich (St.
Louis, MO). CT was purchased from List Biological Laboratories
(Campbell, CA), the purified CTA1/CTA2 heterodimer was
purchased from Calbiochem (La Jolla, CA), and the His-tagged
CTA1 constructs were purified in the laboratory as previously
described [16]. Cell culture reagents were purchased from
Invitrogen (Carlsbad, CA). [
35S]methionine was purchased from
Perkin-Elmer (Boston, MA). Rabbit anti-Hsp90 and anti-PDI
antibodies were purchased from Stressgen Bioreagents Corp.
(Victoria, BC Canada), and the horseradish peroxidase-conjugated
goat anti-rabbit IgG antibody was from Jackson Immunoresearch
Laboratories Inc. (West Grove, PA).
CD and fluorescence spectroscopy
Thermal unfolding experiments were performed using a J-810
spectrofluoropolarimeter equipped with a PFD-425S Peltier
temperature controller (Jasco Corp., Tokyo, Japan). The concen-
tration of His-tagged CTA1 was 70 mg in 220 mLo f2 0 m M
sodium borate buffer (pH 7.0) containing 100 mM NaCl. The
concentration of the commercially available CTA1/CTA2
heterodimer was 73 mg in 220 mL of 20 mM sodium borate
buffer (pH 7.0) containing 100 mM NaCl and, to reduce the
heterodimer, 10 mM b-ME. Thermal unfolding was carried out in
the temperature range of 18–60uC, and samples were allowed to
equilibrate for 4 min at each temperature before measurement.
For fluorescence spectra, CTA1 tryptophan residues were excited
at 290 nm and the fluorescence emission was measured between
300 and 400 nm. CD spectra were recorded from 190 to 320 nm,
which covers both near-UV and far-UV range and thus allowed us
to detect thermal changes in both tertiary and secondary
structures. Each spectrum was averaged from 5 scans. The
observed ellipticity was converted to mean residue molar
ellipticity, [h], in units of degrees6cm
26dmol
21 using:
h ½  ~hobs=cnresl
where hobs is the measured ellipticity in millidegrees, c is the molar
concentration of the protein, nres is the number of amino acid
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millimeters. Fluorescence and CD measurements were taken
sequentially on the same sample in a 0.4 cm optical path-length
quartz cuvette in order to reduce variability in sample-to-sample
recordings. The temperature-dependent unfolding data were
analyzed as previously described [11].
SPR
Experiments were performed with a Reichert (Depew, NY)
SR7000 SPR refractometer. The Reichert Labview software was
used for data collection, and the BioLogic (Campbell, Australia)
Scrubber 2 software was used for data analysis. For experiments
using His-tagged CTA1, sensor slides were prepared as previously
described [11]. For experiments using the CT holotoxin or the
CTB pentamer, a gold plate sensor was coated with the GM1
ganglioside receptor of CT by a procedure described for the
coating of ELISA plates [47]. CT or CTB5 was then bound to the
GM1-coated sensor by perfusing 1 ml of toxin (10 mg/ml) over the
slide for 15 minutes at a flow rate of 5 ml/min.
For experiments involving antibody-coated plates, an EDC-
NHS activation buffer was perfused over a gold-plated glass slide
for 10 min. A 5 min wash with 10 mM phosphate buffered saline
containing 0.05% Tween 20 (PBST) was used to remove the
activation buffer, after which an anti-CTA antibody at 1:2000
dilution in PBST was perfused over the slide for 15 min. Unbound
antibody was removed with a 5 min PBST wash, and the
remaining active groups on the sensor slide were deactivated with
a 3 min exposure to ethanolamine. Following each experimental
condition, bound ligand was removed from the sensor slide with
0.01% imidazole in PBST at pH 5.5.
The following equation was used to determine the stoichiometry
of CT/CTA1-PBA interactions:
stoichiometry~ RPBA=Rtoxin ½  | MW toxin=MW PBA ½ 
where RPBA is the observed response of bound PBA, Rtoxin is the
response of surface-immobilized toxin, and MW is molecular
weight [48].
Translocation assays
For the translocation assay with exogenously applied CT, HeLa
cells were seeded to 6-well plates in complete DMEM medium to
achieve an 80% confluent monolayer after an overnight
incubation at 37uC. Triplicate wells were required for each
condition. To begin the experiment, cells were incubated with
DMEM containing 100 ng/ml of GM1 for 1 h at 37uC. After
washing, the cells were subsequently incubated for 30 min at 4uC
with DMEM containing 1 mg/ml of CT. After further washing,
the cells were returned to 37uC for 2 h in DMEM containing no
additions, 100 mM PBA, or 5 mg/ml of BfA. The cells were then
lifted from the 6-well plate using 750 ml of 0.5 mM ethylenedi-
aminetetraacetic acid in phosphate buffered saline. All cells for
each condition were collected in a single microcentrifuge tube and
spun at 5,0006g for 5 min. The supernatant was discarded and
the pellet was resuspended in 1 ml (SPR assay) or 0.1 ml (Western
blot analysis) HCN buffer (50 mM Hepes pH 7.5, 150 mM NaCl,
2 mM CaCl2, 10 mM N-ethylmaleimide, and a protease inhibitor
cocktail) containing 0.04% digitonin. After 10 min on ice, the
samples were spun at 16,0006 g for 10 min. Both supernatant
(i.e,. cytosol) and pellet (i.e., membrane) fractions were collected
and placed in fresh microcentrifuge tubes. For SPR analysis,
supernatant samples were brought to a final volume of 1 ml in
HCN buffer and perfused over a sensor slide coated with an
anti-CTA antibody. For Western blot analysis, 120 mlo f1 6
sample buffer was added to the pellet and 20 mlo f4 6 sample
buffer was added to the supernatant. Samples were resolved by
SDS-PAGE with 15% polyacrylamide gels, and separate blots
were run for each protein. The anti-Hsp90 antibody was used at a
1:20,000 dilution, the anti-PDI antibody was used at a 1:5,000
dilution, and the horseradish peroxidase-conjugated goat anti-
rabbit IgG antibody was used at a 1:20,000 dilution.
For the translocation assay with plasmid-expressed CTA1,
CHO cells seeded to 80% confluency in 6-well plates were
transfected with pcDNA3.1/ssCTA1 [49] using Lipofectamine
(Invitrogen) according to the manufacturer’s instructions. At 24 h
post-transfection, cells were incubated in methionine-free medium
for 1 h. [
35S]methionine was then added for another hour. Where
indicated, 100 mM PBA was present during both the methionine
starvation and the radiolabeling. Both membrane and cytosolic
fractions from digitonin-permeabilized cells were immunoprecip-
itated with an anti-CTA antibody. SDS-PAGE with Phosphor-
Imager analysis was used to visualize and quantify the immunoi-
solated material. The extent of CTA1 translocation was calculated
with the following equation:
% cytosolic CTA1~CTA1 supernatant signal=
CTA1 supernatant signal ½ zCTA1 pellet signal 
The percentage obtained from untreated control cells was set at
100%, and the percentage obtained from PBA-treated cells was
expressed as a fraction of this value. Previous work has
demonstrated this assay can detect the inhibition of CTA1
translocation in cells lacking Hsp90 function [38].
Trafficking assay
HeLa cells were exposed to GM1 and CT as described above
for the translocation assay. Where indicated, 100 mM PBA or
5 mg/ml of BfA was present in the 37uC chase medium.
Membrane fractions from digitonin-permeabilized cells were
resolved by non-reducing SDS-PAGE with 15% polyacrylamide
gels. Western blot analysis was performed with a rabbit anti-CTA
antibody (1:20,000 dilution) and a horseradish peroxidase-
conjugated goat anti-rabbit IgG secondary antibody (1:20,000
dilution). In the commercially available CT holotoxin, a
substantial fraction of CTA1 is already in a reduced state
(unpublished observations). Thus, for this experiment, we used a
recombinant CT holotoxin produced in Escherichia coli. The
reduced form of CTA1 is initially absent in this recombinant
toxin, so it was possible to clearly detect the reduction of the
CTA1/CTA2 disulfide bond which occurs in the ER.
Toxicity assays
HeLa cells were seeded to 24 well plates and grown overnight to
80% confluency. After a 1 h 37uC incubation with DMEM
containing 100 ng/ml of GM1, the cells were challenged with
various concentrations of CT in the absence or presence of PBA
for 2 h at 37uC. The cells were then washed and exposed to
0.25 ml of ice-cold HCl:EtOH (1:100) for 15 min on ice. Cell
extracts were placed in microcentrifuge tubes and allowed to air
dry overnight. cAMP levels were then determined using an ELISA
cAMP competition assay kit as per manufacturer (GE Healthcare,
Piscataway, NJ) instructions. Background cAMP values obtained
from unintoxicated cells were subtracted from all experimental
values. The maximum cAMP response for the experiment was set
to 100%, and all other values were expressed as a ratio of that
value.
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[38] after approval from the CINVESTAV-IPN Animal Ethical
Committee. For studies involving peritoneal injection of PBA, the
rats were injected 40 minutes before laparatomy with 100 mlo f
PBS or 100 ml of 0.18 M PBA. Injected rats were anesthetized
with Xylacin (6.5 mg/Kg) and Ketamin (34.5 mg/Kg) to perform
laparotomy and expose the small intestines. Four ileal loops of
3 cm with intervening gaps of 2–4 cm between them were then
ligated 20 cm upstream of the ileocecal valve. The loops were
injected with 200 mlo fC T( 3mg/ml in PBS). Control loops from
rats intraperitoneally inoculated with PBS were injected with
200 ml of PBS alone. After injection with CT or PBS, the loops
were returned to the abdominal cavity and the incision was
sutured. The rats were kept alive for 7 h before sacrifice by
cervical dislocation. Ileal loops were photographed and dissected,
and the intestinal contents were collected by gentle pressure. The
volume of fluid in each loop was measured and expressed as a ratio
of the amount (ml) of fluid per unit length (cm) of loop.
Supporting Information
Figure S1 PBA does not prevent the reductive separa-
tion of CTA1 from CTA2. 1 mg samples of the CTA1/CTA2
heterodimer were exposed to 10 mM b-ME for 5 min in the
absence or presence of 100 mM PBA before loading on a non-
reducing SDS-PAGE gel. 1 mg of a CTA1/CTA2 heterodimer
that was not exposed to b-ME was also run on the gel. Samples
were visualized by Coomassie staining, which does not detect the
dissociated 5 kDa CTA2 subunit.
(TIF)
Figure S2 PBA inhibits the thermal unfolding of CTA1-
His6. (A–F): The temperature-induced unfolding of CTA1-His6 in
the absence (A–C) or presence (D–F) of 100 mM PBA was
monitored by near-UV CD (A, D), fluorescence spectroscopy (B,
E), and far-UV CD (C, F). The change in color from blue to red
corresponds to a change in temperature from 18uCt o6 0 uC. (G–I):
Thermal unfolding profiles for CTA1-His6 in the absence (red) or
presence (blue) of 100 mM PBA were derived from the data
presented in panels A–F. (G): For near-UV CD analysis, the mean
residue molar ellipticities at 280 nm ([h]280) were plotted as a
function of temperature. Tm values of 33uC and 36uC were
recorded for CTA1-His6 in the absence and presence of PBA,
respectively. (H): For fluorescence spectroscopy, the maximum
emission wavelength (lmax) was plotted as a function of
temperature. Tm values of 35.5uC and 39uC were recorded for
CTA1-His6 in the absence and presence of PBA, respectively. (I):
For far-UV CD analysis, the mean residue molar ellipticities at
220 nm ([h]220) were plotted as a function of temperature. Tm
values of 35uC and 45uC were recorded for CTA1-His6 in the
absence and presence of PBA, respectively.
(TIF)
Figure S3 PBA does not inhibit the thermal unfolding of a
CTA1 construct lacking the A13subdomain, CTA11–168NHis6.
(A–F): The temperature-induced unfolding of CTA11–168?His6 in
the absence (A–C) or presence (D–F) of 100 mM PBA was
monitored by near-UV CD (A, D), fluorescence spectroscopy (B,
E), and far-UV CD (C, F). The change in color from blue to red
corresponds to a change in temperature from 18uCt o6 0 uC. (G–I):
Thermal unfolding profiles for CTA11–168?His6 in the absence
(red) or presence (blue) of 100 mM PBA were derived from the
data presented in panels A–F. (G): For near-UV CD analysis, the
mean residue molar ellipticities at 280 nm ([h]280) were plotted as
a function of temperature. Tm values of 32.5uC and 33uC were
recorded for CTA11–168?His6 in the absence and presence of PBA,
respectively. (H): For fluorescence spectroscopy, the maximum
emission wavelength (lmax) was plotted as a function of
temperature. Tm values of 34uC and 33.5uC were recorded for
CTA11–168?His6 in the absence and presence of PBA, respectively.
(I): For far-UV CD analysis, the mean residue molar ellipticities at
220 nm ([h]220) were plotted as a function of temperature. Tm
values of 36uC and 35.5uC were recorded for CTA11–168?His6 in
the absence and presence of PBA, respectively.
(TIF)
Figure S4 Partial unfolding of reduced CTA1/CTA2 is a
reversible process. Fluorescence measurements were conduct-
ed on a reduced CTA1/CTA2 heterodimer. CTA1 tryptophan
residues were excited at 290 nm and the fluorescence emission was
measured between 300 and 400 nm. The simulated curve for a
reduced CTA1/CTA2 heterodimer heated from 18uCt o6 5 uC
was used to fit the experimental data in both A and B. (A)
Temperature dependence of the maximum emission wavelength
of tryptophan fluorescence when reduced CTA1/CTA2 was
heated from 18uCt o6 5 uC (filled circles) and then cooled from
65uCt o1 8 uC (open circles). (B) Temperature dependence of the
maximum emission wavelength of tryptophan fluorescence when
reduced CTA1/CTA2 was heated from 18uCt o3 7 uC (filled
circles) and then cooled from 37uCt o1 8 uC (open circles).
(TIF)
Figure S5 Calculation of cytosolic CTA1 from SPR-
based translocation assays. The association rate constants
for the CTA standards from Fig. 4B were plotted as a function of
protein concentration (closed circles). The association rate
constants for CTA1 obtained from the cytosol of untreated (open
circle) or PBA-treated (open square) cells were then plotted on the
standard curve. A CTA1 concentration of 0.24 ng/ml was
calculated for untreated cells, and a CTA1 concentration of
0.08 ng/ml was calculated for PBA-treated cells.
(TIF)
Figure S6 Secretion of CTA1 from PBA-treated cells.
HeLa cells pulse-labeled at 4uC for 30 min with 1 mg/ml of CT
were chased for 2 hr at 37uC in toxin-free medium that lacked (no
treatment) or contained 100 mM PBA (+PBA). Media samples
from these cells, from cells incubated with 5 mg/ml of BfA (+BfA),
and from unintoxicated control cells were then analyzed by SPR
with a sensor slide that had been coated with an anti-CTA
antibody. CTA standards (10 ng/ml and 1 ng/ml) were also
perfused over the sensor slide as positive controls. One of three
representative experiments is shown. At the end of each
experiment, bound sample was stripped from the sensor slide.
(TIF)
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